1. Home
  2. PVH vs ACAD Comparison

PVH vs ACAD Comparison

Compare PVH & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PVH Corp.

PVH

PVH Corp.

N/A

Current Price

$76.21

Market Cap

3.6B

ML Signal

N/A

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$29.63

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PVH
ACAD
Founded
1881
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.3B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
PVH
ACAD
Price
$76.21
$29.63
Analyst Decision
Buy
Buy
Analyst Count
16
22
Target Price
$90.53
$30.55
AVG Volume (30 Days)
864.3K
1.8M
Earning Date
06-03-2026
05-06-2026
Dividend Yield
0.16%
N/A
EPS Growth
N/A
69.12
EPS
1.90
0.20
Revenue
$8,950,200,000.00
$726,437,000.00
Revenue This Year
$1.89
$18.80
Revenue Next Year
$1.86
$11.70
P/E Ratio
$41.32
$147.90
Revenue Growth
3.44
40.45
52 Week Low
$59.60
$19.69
52 Week High
$100.75
$30.96

Technical Indicators

Market Signals
Indicator
PVH
ACAD
Relative Strength Index (RSI) 43.83 N/A
Support Level $69.08 N/A
Resistance Level $79.95 N/A
Average True Range (ATR) 2.56 0.00
MACD -0.73 0.00
Stochastic Oscillator 24.19 0.00

Price Performance

Historical Comparison
PVH
ACAD

About PVH PVH Corp.

PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, roughly 1,400 standalone stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: